Daily question: When will the epidemic subside?
In recent years, due to the impact of the epidemic, even daily life has been seriously affected.
The current global epidemic is still at a high level, and the number of new coronary pneumonia infections in Europe is increasing rapidly. Disease control experts pointed out that a new round of epidemic is sweeping Europe:
The domestic prevention and control situation is also severe and complex. Local clustered epidemics have been reported in many places across the country, with multiple transmission chains, and the pressure to prevent external imports is also increasing.
However, good news has also come, the first domestically approved special medicine for new crown has been launched.
01
New Coronavirus specific drugs are on the market, with a price of 10,000
On July 7, Tengsheng Boyao and its holding company Tengsheng Huachuang announced that
its new Coronavirus neutralizing antibodies (combination therapy of ambavizumab and romisvizumab) is commercially available in China, and the first batch of antibody drugs have been commercially released.
This drug is also the first domestically produced new crown neutralizing antibody combination therapy drug to be approved.
The first batch of drugs totaled 100 servings, and the whole process was stored in a cold chain environment of 2-8℃.
On July 11, the drug handover was officially completed.
1. What is the actual clinical treatment effect?
Laboratory research and tests show that this drug only requires a very low antibody concentration, that is, 16.61 micrograms/ml, to inhibit 90% of the BA.4 or BA.5 Omickron variant strain,
and can reduce the hospitalization and mortality rate of high-risk COVID-19 patients by 80%.
After the antibody binds to the virus, it can quickly reduce the virus concentration and titer in the patient, and the infection rate will naturally decrease.
It is understood that the dosage of the combination therapy of ambavirzumab and romisvirzumab is the highest among all approved neutralizing antibodies at home and abroad. The combination therapy for
per person is composed of 1,000 mg of ambavirzumab and 1,000 mg of romisvirzumab.
uses intravenous infusion. It is intravenous after infusion in about an hour. It is enough to take one dose only once, and no further treatment is required.
On July 9, after the first batch of drugs were delivered to Shenzhen Third People's Hospital , an 82-year-old confirmed case in the hospital became the first clinical user after the drug was commercially launched.
This case suffers from various underlying diseases such as hypertension , coronary heart disease , chronic heart failure, and other underlying diseases, and has a high viral load, which is prone to developing severe diseases.
At present, the elderly’s various immune mechanisms have been effectively improved, the amount of virus has dropped sharply, and the effect of medication is relatively obvious.
And in past clinical treatment, ambavizumab/romisvizumab combined therapy has indeed shown outstanding results.
Academician of the Chinese Academy of Engineering Zhong Nanshan said on the 8th that based on the observation of clinicians, the combination therapy of can rapidly reduce the high viral load in a relatively short time (2-3 days).
Therefore, This combination therapy is very effective in treating patients with high viral load.
At the same time, its clinical adaptation range is relatively wide and its usage time is relatively loose. It has good results for both early patients and middle and late patients.
It can be said that in the fight against the epidemic, this new crown special drug will provide more means, paths and methods for treating critically ill patients.
2. The drug pricing is within 10,000 yuan
Currently, the combination of ambavirumab and romisvirumab are combined with domestically marketed using an independent pricing model.
Overseas, the business model of this drug is a government procurement model. For example, the government procurement price per person is between 1,500 and 2,000 US dollars under the scale of millions of people.
, and its domestic pricing is lower than the global level, is basically within 10,000 yuan.
02
new crown special medicine, can medical insurance be reimbursed?
From a global perspective, the price of new crown specialty drugs in my country is relatively low, but it is also a great burden for many ordinary working-class people.
But the good news is , patients can go to medical insurance to settle.
Considering the particularity of the development of the new crown pneumonia epidemic, in order to ensure that new crown patients do not seek medical treatment due to cost issues,
The National Health Insurance Administration adopts a special reimbursement policy for patients with pneumonia confirmed suspected and confirmed new coronavirus infection:
According to "New Coronavirus" Viral Pneumonia Diagnosis and Treatment Plan (Trial Ninth Edition)》 stipulates that during the epidemic, drugs, diagnosis and treatment projects and medical consumables that meet the diagnosis and treatment plan for pneumonia infected by the new coronavirus formulated by the health and health department will be temporarily included in the medical insurance fund payment scope, and the hospitalization deduction standard will be cancelled to ensure that patients do not seek medical treatment due to cost issues.
The combination therapy of ambavirumab and romisvirumab has been included in the "Diagnosis and Treatment Plan for the New Coronavirus Pneumonia (Trial Ninth Edition)", and the medical insurance fund is paid according to regulations.
Since March 22 this year, medical insurance bureaus of many provinces and cities have successively included ambavirb and romisvirb combination therapy in the scope of medical insurance fund payment.
And not only this drug, but also other drugs within the diagnosis and treatment plan can be reimbursed through medical insurance.
03
How can we strengthen the protection of the new crown in addition to medical insurance?
The epidemic has been repeated over and over again. In addition to taking precautions, we can also provide timely guarantees for ourselves and our families.
For example, epidemic prevention insurance is specifically for COVID-19:
In addition to the regular accidental death/disability protection, it also has additional COVID-19 death responsibility, diagnosis allowance, isolation allowance, etc.
products are cheap, most of which range from ten to ten yuan, and can be paid up to hundreds of thousands.
Under the current severe epidemic prevention situation, if you live in a densely populated city or often need to go out, it is still necessary to prepare it.
For example, Huatai Anti-epidemic insurance , up to 80 years old, can be invested, including isolation allowances and traffic accident protection, and you can get 30 days of protection for only 8.8 yuan.
In addition, other more comprehensive protections are needed, and protection insurance types such as medical insurance , critical illness insurance , accident insurance and term life insurance are needed.
For example, if you are hospitalized due to the new crown, you can also reimburse the medical expenses incurred by hospitalization and outpatient clinics.
0,000 COVID-19 comes, these insurances can also prevent our economy and life from being affected too much.
04
daddy summary
The launch of the new crown special medicine is definitely good news for epidemic prevention and control, and the treatment of patients has also reached a higher level.
If medical insurance can also be reimbursed, it can relieve the great economic pressure for patients' treatment.
But the best way is to protect yourself from infection and try to ensure it as early as possible.
